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Abstract
Background: The functional and molecular alterations of nerve growth factor (NGF) and Prostaglandin E2 (PGE2) and its
receptors were studied in bladder and urine in streptozotocin (STZ)-induced diabetic rats.
Methodology/Principal Findings: Diabetes mellitus was induced with a single dose of 45 mg/kg STZ Intraperitoneally (i.p)
in female Sprague-Dawley rats. Continuous cystometrogram were performed on control rats and STZ treated rats at week 4
or 12 under urethane anesthesia. Bladder was then harvested for histology, expression of EP receptors and NGF by western
blotting, PGE2 levels by ELISA, and detection of apoptosis by TUNEL staining. In addition, 4-hr urine was collected from all
groups for urine levels of PGE2, and NGF assay. DM induced progressive increase of bladder weight, urine production,
intercontraction interval (ICI) and residual urine in a time dependent fashion. Upregulation of Prostaglandin E receptor (EP)1
and EP3 receptors and downregulation of NGF expression, increase in urine NGF and decrease levels of urine PGE2 at week
12 was observed. The decrease in ICI by intravesical instillation of PGE2 was by 51% in control rats and 31.4% in DM group at
week 12.
Conclusions/Significance: DM induced hyposensitive underactive bladder which is characterized by increased
inflammatory reaction, apoptosis, urine NGF levels, upregulation of EP1 and EP3 receptors and decreased bladder NGF
and urine PGE2. The data suggest that EP3 receptor are potential targets in the treatment of diabetes induced underactive
bladder.
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Introduction
Diabetes Mellitus (DM), a chronic metabolic condition, is a
rising health concern worldwide with significant medical and
health economic issues. More than 80% of diabetes patients suffer
lower urinary tract complication [1]. Diabetic bladder dysfunction
(DBD) is a complex phenomenon and involves different patho-
physiology, mechanisms, and time dependent morphological and
functional manifestations of bladder [2]. DBD was earlier
described as diabetic cystopathy and characteristics include
diminished sensation of bladder fullness, reduced bladder
contractility and increased residual urine [3,4,5].
Recent studies characterize DBD as biphasic with overactive
bladder symptoms in the early phase and later phase characterized
by hyposensitive and underactive bladder with poor bladder
emptying. Later phase complications of DBD leads to chronic
urine retention and recurrent urinary tract infections. These
functional changes may induce compensatory bladder tissue
remodeling such as bladder wall thickening that is promoted by
oxidative stress and inflammation in streptozotocin induced
diabetic rats [6]. With progression of diabetes, DBD can morph
into a state that can be described as detrusor underactivity and
hyposensitive bladder [7,8] or diabetic cystopathy.
Prostanoids, particularly PGE2 are local autocoids and play an
important role in micturition reflex. PGE2 synthesis occurs locally
in urothelium and smooth muscle [9,10]. Diabetes impairs
Prostaglandin E2 and F2 release from rat urothelium preparations
[11]. PGE2 can act directly on the bladder smooth muscle, and
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also sensitize capsaicin sensitive afferent nerves [12]. In rats and
humans, intravesical administration of PGE2 stimulates reflex
micturition and causes bladder overactivity through EP receptors
(EP1–EP4) [12,13,14]. The differences in the functions and
localization of EP receptors, determine the influence of different
EP receptors in micturition processing. EP1 and EP3 receptors
expressed in smooth muscle and other tissues[15,16,17,18] are
known to cause contraction of non-diseased and cystopathic
bladder [19]. However the role of differentially expressed EP1 and
EP3 receptors in diabetes induced hyposensitive bladder is not
clear.
The diagnosis of diabetic cystopathy relies on urodynamic
study, which is invasive and uncomfortable for some patients. A
non-invasive biomarker reflecting the different stage and condition
of diabetic cystopathy is currently lacking. Nerve Growth Factor
(NGF) is produced by both urothelium and smooth muscle in
bladder, and believed to be a significant mediator in the
modulation of various urothelial responses in diabetic cystopathy
[20,21]. NGF levels decreased in the bladder and L6 and S1 dorsal
root ganglion 3 weeks after STZ injection in a time dependent
fashion, and the hyposensitive bladder could be reversed by NGF
gene therapy at week 8 [22].
In the present study, we investigated the Streptozotocin induced
DM rat model at baseline 4 and 12 weeks post STZ injection to
study: 1) the time dependent changes in urine biomarkers of NGF,
PGE2; 2) differential expression of EP1and EP3 receptors, NGF
and PGE2 in control and diabetes (hyposensitive bladder); 3)
diabetes induced apoptotic changes. We further studied the effects
of intravesical PGE2 in diabetic hyposensitive bladder.
Materials and Methods
Animals
Female Sprague-Dawley (SD) rats (220–280 gm), aged 12 to 16
weeks were procured from Bio LASCO Taiwan Co., Ltd. All
experimental procedures performed were approved by the
Institutional Animal Care and Use Committee of Kaohsiung
Chang Gung Memorial Hospital (CGMH 201111183). The rats
were acclimated for one week under standardized temperature
(21–22uC) and humidity (50–60%) with free access to food and
water before the experiment. Streptozotocin (STZ; 45 mg/kg) was
injected intraperitoneally to induce DM. Blood glucose levels were
measured 5 days after STZ administration. Only rats with blood
glucose .350 mg/dl were used in the study. A total of 54 rats
were used in this study (N= 18; control group, DM 4 wk, DM
12 wk). Among the 54 rats, 18 rats were used for CMG involving
intravesical PGE2 study and 36 rats were used for all other studies.
Cystometrogram (CMG)
Animals (N= 8, per group) were anesthetized by subcutaneous
injection of urethane (1.2 g/kg). A polyethylene tubing (PE-50)
was inserted into the bladder through the urethra and connected
via a three-way stopcock to a pressure transducer and to a syringe
pump for recording intravesical pressure and for infusing solutions
into the bladder. To elicit repetitive voiding, CMG was performed
by filling the bladder with saline (0.08 ml/min). Intercontraction
interval (ICI), the average time between contractions of reflex
bladder contractions; amplitude (the peak pressure minus the basal
pressure during each contraction period); pressure baseline (PB),
the pressure immediately after the reflex contraction); and pressure
threshold (PT), the pressure immediately before the reflex
contraction were recorded. Measurements in each animal
represented the average of 3 to 5 bladder contractions after an
initial 60 minute stabilization period. At the end of CMG
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recording, the saline infusion was stopped after confirming the first
micturition, and then the residual urine was collected and
measured.
Urine Cytokines
Urine samples were collected in iced bowls for 4 hr from 9 rats
(N= 9) at baseline, 4 week, and 12 week post-STZ injection. The
collected urine was centrifuged at 3000 rpm for 10 minutes at
4uC. The supernatants were immediately frozen at 280uC and
kept until further analysis. On the day of analysis, frozen urine
samples were thawed at room temperature for measurement of
urine PGE2 (Cayman, Michigan, USA), NGF (EIAab, Wuhan,
China) using ELISA kits for rat urine according to the
manufacturer’s instructions. The NGF concentrations for each
time point were normalized to the creatinine concentration in
urine and are expressed as the picograms excreted per milligram of
creatinine.
Western blot analysis for EP1, EP3, and NGF expression
Rats were euthanized in control group and in experimental
groups (N=6, per group) at 4 and 12 weeks post STZ injection.
The bladder was weighed and subjected to Western blot analysis
of EP1and EP3 receptor expression according to the standard
protocol and following our previous study [23]. Bladder was
homogenized in protein extraction solution (T-PER; Pierce
Biotechnology) prior to sonication and purification. Total protein
was measured using Bradford protein assay (Bio-Rad Laborato-
ries, Hercules, CA). Lemmli buffer system was used to run the
SDS-polyacrylamide gel electrophoresis (PAGE). Briefly, 30 mg
protein aliquot was loaded onto 8% polyacrylamide gel, electro-
phoresed at a constant voltage of 100 V for 1 h and transferred to
Hybond-P PVDF Membrane (Amersham Biosciences). Blocking
agent was used to block the membrane and then immunoblotted
overnight at 4uC. The primary antibody concentration of mouse
anti-actin monoclonal antibody (Chemicon, USA; MAB1501);
rabbit anti-NGF polyclonal antibody (Santa Cruz, USA; SC548)
and rabbit anti-EP1 and EP3 receptor polyclonal antibody
(Cayman, MI, USA; No.101740 and 101760, respectively) were
Figure 1. Representative traces of continuous cystometrograms (CMG) in urethane anesthetized rats (N=8 per group; A- Control,
B- DM week 4 and C- DM week 12). A with a normal voiding pattern, B and C with a hyposensitive underactive bladder.
doi:10.1371/journal.pone.0102644.g001
Table 2. Cystometric analysis of the experimental groups.
N=8 per group (SEM) ICI, min Amp, cmH2O BP, cmH2O PT, cmH2O RU(gm)
Control 11.3(0.1) 26.2(1.7) 1.1(0.2) 4.1(0.5) 0.1(0.1)
DM 4 wk 23.8(2.9)* 30.4(1.6) 1.3(0.2) 3.9(0.4) 2.7(0.4)**
DM 12 wk 29.9(2.6)** 29.1(1.8) 1.1(0.2) 4.2(0.4) 2.9(0.7)**
ICI: intercontraction interval; Amp: amplitude; BP: baseline pressure; PT: pressure threshold; RU: Residual urine.
*P,0.05 vs control;
**P,0.01 vs control.
doi:10.1371/journal.pone.0102644.t002
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used as follows: Mouse anti-actin (1:10000); rabbit anti-NGF
(1:1000); rabbit anti-EP1 (1:200); rabbit anti-EP3 (1:500). The
molecular weight of NGF, EP1 receptor, and EP3 receptor is
27 kDa, 42 kDa and 52 kDa, respectively as per the manufactur-
er. Washed membranes were incubated with secondary antibody
using 5% defatted milk powder in Tris buffered saline TBS for 2 h
at room temperature using a horseradish peroxidase-linked anti-
rabbit or anti-mouse Immuglobulin G. Visualized the Western
blots using enhanced chemiluminescence (ECL) detection system
(Amersham Biosciences). b-actin was used as the internal control.
Quantitative analysis was done using LabWorks Image Acquisition
and Analysis software.
ELISA analysis of PGE2
Enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI,
USA, Catalog No.514010) were used to measure levels of PGE2 in
rat bladder according to the directions of manufacturer. In brief,
frozen rat bladder was homogenized in 0.1 mol/L phosphate-
buffered saline with 1 mmol/L EDTA and 10 mmol/L indo-
methacin was added. Homogenization samples were suspended in
ethanol (4 times of sample volume) and incubated for 5 min, and
then samples were centrifuged at 3000 g at 4uC for 10 min. The
supernatant was transferred into a clean test tube cautiously. In
enzyme immunoassay buffer the resulting samples were re-
dissolved and transferred to an antibody precoated 96-well plate.
Total Activity (TA), Non Specific Binding (NSB) and substrate
blank wells for comparison were marked in antibody-coated wells.
In to the zero standard (B0; 50 mL) and NSB (100 mL) wells, assay
buffer (a buffered protein base) was added. 50 mL of diluted
samples and PG standards were pipetted into the residual wells.
Conjugate of high-sensitivity (50 mL) was added to each well, apart
from the TA and substrate blank wells. Solution of High-sensitivity
antibody (50 mL) was dispensed into every well, not including the
NSB, TA and substrate blank wells. Adhesive strips were used to
cover the wells till reaction. Washing was performed 5 times with
washing buffer and then all liquid was removed from the wells.
Five ml of conjugate was added to TA well and 200 mL of Ellman’s
reagent was added to each well. PGE2 concentration was
determinedd after absorbance measurement at 405 nm with a
microplate reader (BIO-TEK, mQuant, USA) [24].
Histology and immunohistochemistry
After the CMG study, 6 animals from each group were deeply
anesthetized with pentobarbital and sacrificed via transcardiac
perfusion, first with Krebs buffer followed by 4% paraformalde-
hyde fixative. Harvested bladder was weighed and divided into
two parts. One part was fixed in 10% buffered formaldehyde for
24–48 h, and then embedded in paraffin, and stained with
hematoxyline and eosin or subjected to immunohistochemistry
analysis for apoptosis with TUNEL stain (terminal deoxynucleo-
tidyl-mediated deoxyuridine triphosphate nick end labeling stain)
using a commercially available kit (Detection Kit POD, Boehrin-
ger Mannhein, Mannhein, Germany). Remaining part of bladder
was frozen in liquid nitrogen and stored at 280uC until use.
Inflammation associated with STZ induced cystopathy was graded
by a score of 0–3 as follows: 0- no evidence of inflammatory cell
infiltrates or interstitial edema; 1- mild (few inflammatory cell
infiltrates and little interstitial edema); 2- moderate (moderate
amount of inflammatory cell infiltrates and moderate interstitial
edema); 3- severe (diffuse presence of a large amount of
inflammatory cell infiltrates and severe interstitial edema). A
single blinded research technician graded the bladder histology.
The proportion of TUNEL positive nuclei per 500 nuclei was
quantified at 6400 magnification using a 10610 grid in the
eyepiece in 4 fields.
Intravesical PGE2 administration
Stock solutions (0.01 M) of PGE2 (Sigma) were made in absolute
ethanol and then further diluted in saline (100 mM) before use.
After a baseline measurement was established during saline
infusion, 100 mM PGE2 was infused into the bladder (N= 6, per
group) at 0.08 ml/min to acutely simulate bladder hyperactivity.
The CMG was performed in control and STZ rats at week four
and week 12 to test the response of DM rats to intravesical PGE2.
Statistical analysis
Quantitative data are expressed as mean 6 standard error.
Statistical analyses were performed using t-test or one way
ANOVA, with Dunn’s multiple comparisons test where applica-
ble, with p,0.05 considered significant.
Table 3. Analysis of urine cytokines in DM rats.
N=9 (SEM) PGE2/creatinine (pg/mg) NGF/creatinine (pg/mg)
Baseline 25.49 (9.21) 0.52 (0.07)
DM 4 wk 22.31 (9.01) 2.83 (0.45)*
DM 12 wk 7.53 (0.86)* 3.25 (0.54)*
*P,0.05 vs baseline.
doi:10.1371/journal.pone.0102644.t003
Figure 2. Western blot analysis of EP1, EP3 receptors and NGF
expression in the bladder (N=6, per group). At DM week 12, the
protein amount of EP3 was significantly increased (1.4 fold) and NGF
was significantly decreased (60.6%) than the control rat. There was no
significant change of EP1 receptors.
doi:10.1371/journal.pone.0102644.g002
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Results
DM induced physiological changes
Body weight of diabetic rats decreased by the 4th and 12th week
following STZ injection. The decrease was found to be significant
at week 4 compared to the control group. At week 12 a significant
increase in body weight was noted as compared to week 4.
Significantly increased bladder weight was observed till 12 weeks.
Significant rise in the blood glucose and urine production was
noted compared to control group. Progressive increase of bladder
weight, urine production is considered signs for developing DBD
(Table 1).
DM induced cystometry changes
CMG analysis showed an increased ICI at week 4 and 12 when
compared to the control group. Time dependent increase in ICI
(2.1 fold and 2.6 fold increase) and residual urine (2.7 and 2.9 ml)
at week 4 and 12 confirms the development of hyposensitive
underactive bladder due to DM (Table 2; Fig. 1). In the current
study, we did not observe overflow incontinence from the control
rats as well as the DM rats. Non-voiding contractions were
observed in some DM rats (Fig. 1 C).
DM induced changes in urine markers
Diabetic cystopathy gradually decreased the PGE2 levels in the
urine at week 4 (12.5% decrease) and at week 12 (70.5% decrease)
as compared to the baseline levels. The decrease of urinary PGE2
was significant at week 12. The urine NGF level was progressively
increased at week 4 (5.4 fold increase) and week 12 (6.25 fold
increase) as compared to baseline (Table 3).
DM induced changes in the bladder expression of EP
receptors, NGF and PGE2
Western blot analysis relative to anti-actin demonstrated the
upregulation of EP1 and EP3 receptors especially 1.4 fold
upregulation of EP3 receptor was observed at week 12. NGF
level was found to be significantly down regulated (60.6%) at DM
week 12 (Table 4 and fig. 2). Expression levels of PGE2 also
showed an upregulation at DM week 4 and week 12, however, it
was not significant.
Histology and TUNEL staining
DM bladder sections showed thickening of submucosal layer
and increased inflammatory cell infiltrates (Fig. 3D, G) as
compared to the control (Fig. 3A). There was a trend of increased
percentage of trichome staining at week 12 which was indicative of
inflammation (Fig. 3B, E, H). The increased apoptosis was shown
by TUNEL staining in DM group as compared to control (Table 5
and Fig. 3).
Intravesical PGE2 (100 mM) on CMG
ICI was significantly decreased after intravesical instillation of
PGE2 (51% decrease) in the control rats. However, rats at 12weeks
post –STZ injection showed a tendency to reduce response (ICI
31.4% decrease; p = 0.0849, vs control) to PGE2 instillation.
(Table 6; Fig. 4).
Table 4. Bladder histology, western blotting for detection of EP1, EP3, NGF, and ELISA for detection of PGE2.
N=6, Per group (SEM) EP1 EP3 NGF PGE2
Control 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00)
DM 4week 1.09 (0.15) 1.34 (0.17) 0.47 (0.10)* 1.71 (0.57)
DM 12week 1.29 (0.16) 1.43 (0.07)* 0.42 (0.10)** 1.31 (0.46)
*P,0.05, and
**P,0.01 vs Control.
doi:10.1371/journal.pone.0102644.t004
Figure 3. Photomicrographs of bladder sections (N=6, per group). A, B, C: Control Group; D, E, F: DM week 4; G, H, I: DM week 12, (6200). A,
D, G (H and E stain); B, E, H (trichome stain); CFI (TUNEL stain). DM rat at week 12 (G, H) showed increase of inflammatory reaction compared to the
control rat (A, B). DM rat at week 4 (F) showed significant increase of TUNEL stain (9.4 fold) compared to the control rat (C).
doi:10.1371/journal.pone.0102644.g003
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Discussion
Diabetes is associated with a systemic inflammation, neuropa-
thy, and metabolic syndrome, all of which have been linked to
DBD [25]. Pathophysiology of diabetic cystopathy is multifactorial
and may result from physiological changes in the detrusor smooth
muscle cell, the innervation, or dysfunction of urothelium,
however, the underlying mechanism is not known [6]. The
observation of hyposensitive bladder at week 12 post STZ
injection implicates dysregulated paracrine signaling and remod-
eling of bladder tissue that is characteristic of diabetic cystopathy
Table 5. TUNEL assay and histology scores in rat bladder.
N=6 per group (SEM) TUNEL Staining Trichrome stain, percentage Edema score Inflammatory Cells
Control 2.70 (0.80) 31.77 (6.04) 0.43 (0.30) 0.32 (0.05)
DM 4 wk 25.40 (5.00)* 32.50 (4.08) 1.57 (0.43) 1.73 (0.21)**
DM 12 wk 17.00 (2.90) 46.10 (4.15) 2.0 (0.44)* 2.2 (0.21)***
*P,0.05 and
**P,0.01 and
***P,0.0001 VS Control.
doi:10.1371/journal.pone.0102644.t005
Figure 4. Representative traces of continuous cystometrograms (CMG) in urethane anesthetized rats (N=6, per group). Intravesical
PGE2 induced bladder overactivity, which effects were decreased at DM week 4 and week 12. A (Control, saline), B (Control, PGE2-100 mg); C (DM
week 4, saline), D (DM week 4, PGE2 – 100 mg); E (DM week 12, saline) F (DM week 12, PGE2).
doi:10.1371/journal.pone.0102644.g004
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[1]. Cystometric results (Fig. 1C) are consistent with increased
bladder capacity associated with hyposensitive underactive blad-
der.
The STZ induced diabetes is confirmed in the present study by
increase in blood glucose and urine production. Increased bladder
weight and residual urine indicate the incomplete bladder
emptying in the animals. Increase in the bladder weight of STZ
induced DM rats may results from edematous change in the
hyposensitive distended bladder. The role of prostaglandins in
maintaining the barrier properties and low osmotic water
permeability is known [26]. The upregulation of PGE2 and EP1
and EP3 receptors in our study might indicate an adaptive
response to decrease osmotic water permeability [26] and counter
the edematous changes.
The increase of ICI and residual urine without an accompa-
nying decrease of the contraction amplitude in these observations
mimic the situation of hyposensitive bladder (Table 1, Fig. 1). The
hyposensitive bladder may arise from compromised nerve
function, which may occur earlier than impairment of muscle
contractility as neurons are more sensitive to hyperglycemia than
muscles [2]. Sensory and sympathetic neurons require NGF for
survival and maintenance [21]. The significant decrease in the
expression of NGF in diabetic bladder is correlated with the
progression of the underactive bladder at week 12 (Table 4). It was
postulated that impaired functions of A-d and C-fiber bladder
afferent pathways in diabetic cystopathy is associated with the
progressive decline in NGF [27]. On the contrary, NGF over
expression in the bladder and bladder afferent pathways is
involved in the emergence of hyperexcitability in bladder C-fiber
sensory pathways [28,29]. Previous studies show that down
regulated NGF expression in the urinary bladder of diabetic rats
leads to its decreased transport to their afferent pathways, which
contributes to diabetic cystopathy [22,30].
Interestingly, we found increased urine levels of NGF together
with lowered bladder NGF levels, which may be related to the
inflammation, edema and apoptosis in hyposensitive bladder
(Table 5; Fig. 3). It has been suggested that NGF is required for the
maintenance of the neurons, the ability to resist apoptosis and
regenerative capacity [30]. Previous studies have reported that
there is a deficiency of NGF in diabetes [26,30], which is
compatible with the current finding of decreased bladder NGF
level in our DM rats. Furthermore, inflammation and apoptosis in
bladder might cause the loss of NGF binding receptors, which
leads to increased expulsion of NGF in bladder and increased
urine NGF level. Sasaki et al. has proved the concept that NGF
gene therapy could restore the bladder NGF levels and rescue the
bladder function in STZ induced diabetic cystopathy [22].
Cyanidin-3-O-b-D-glucopyranoside (C3G), a free radical scaven-
ger to attenuate oxidate stress, has been shown to restore the
bladder function in STZ induced DBD by decrease in apoptosis
and increase in the NGF bladder levels [31,32,33]. However, the
change of urine NGF levels were not reported in conjunction with
the recovery of bladder function. It would be interesting to know
whether the urine NGF level could serve as a surrogate marker to
monitor DBD.
Decreased urine levels of PGE2 may be related to loss of cells
secreting PGE2 in hyposensitive diabetic bladder epithelium,
which is known to impair voiding function and lead to urinary
retention [12,13]. It is known that prostanoid is synthesized locally
from both bladder smooth muscle and urothelium [9] and PGE2
modulates bladder function at detrusor muscle as well as efferent
and capsaicin sensitive afferent nerves [13,34]. The deficiency of
bladder NGF in DM rats leads to impairment of capsaicin
sensitive afferent nerve [26], which tends to a decrease of response
to intravesical PGE2 instillation. The present study also aimed to
delineate the association between PGE2 and the contraction
receptors EP1 and EP3 to develop a therapeutic target for
underactive bladder. The expression of EP1 and EP3 receptors in
control and upregulation of EP1 and EP3 receptors in the
hyposensitive bladder indicates the role of PGE2 in micturition
function might partly mediate through these 2 receptors (Table 4;
Fig. 2). The upregulation of EP1 and EP3 receptors in DBD may
be compensatory changes to maintain bladder contractility
[35,36]. DBD is also known to cause alteration in expression of
cannabinoid and TRPV1 receptors in bladder and urinary tract
[37,38].
EP1 and EP3 are stimulatory receptors, mediating smooth
muscle contraction by an increase of phosphoinositol turnover and
calcium mobilization, or a decrease of adenylate cyclase and
cAMP levels, respectively [39,40]. In guinea pig uterus, PGE2 was
shown to be agonists for both EP1 and/or EP3 receptors, but was
mostly acting via EP3 receptors [18]. Further studies are needed to
clarify the precise link between PGE2 and EP1 and EP3 receptors
with regard to the functional changes in urothelium and detrusor
in the DM hyposensitive bladder. Intravesical PGE2 induced a
decrease in the inter contraction interval (Table 6; Fig. 4) at DM
week 4 and 12, which may be caused by direct action on the
smooth muscle and activation of capsaicin sensitive afferent
pathway leading to phasic contractions [13]. DM is known to lead
loss of phasic contractions in bladder due to changes in non-
adrenergic noncholinergic transmission and intravesical PGE2
may be able to restore it [41].
Table 6. Effects of intravesical PGE2 on CMG parameters.
N=6 per group (SEM) Treatment ICI (min) Amp (cmH2O) PB (cmH2O) PT (cmH2O)
Control Saline 14.1 (1.4) 26.6 (2.7) 0.9 (0.3) 3.5 (0.3)
PGE2 100 uM 6.9 (1.0)** 25.8 (2.0) 2.1 (0.4)* 5.7 (0.4)**
DM 4 W Saline 22.3 (3.1) 30.2 (2.4) 0.8 (0.2) 3.1 (0.3)
PGE2 100 uM 14.0 (1.9)* 31.1 (3.3) 1.9 (0.5) 4.2 (0.4)
DM 12 W Saline 31.9 (3.4)# 26.9 (1.6) 1.3 (0.4) 4.2 (0.4)
PGE2 100 uM 21.9 (5.3) 28.1 (2.0) 2.4 (0.5) 5.4 (0.4)*
ICI: intercontraction interval; Amp: amplitude; BP: baseline pressure; PT: pressure threshold;
*P,0.05 and
**P,0.01;
#P,0.01 (control vs DM 12 W).
doi:10.1371/journal.pone.0102644.t006
Characterization of Diabetic Induced Hyposensitive Underactive Bladder
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102644
In conclusion, we observed inflammation, apoptosis, and
upregulation of EP1 and EP3 receptors in DM hyposensitive
underactive bladder. Furthermore, changes in the expression of
PGE2 and NGF were also noted, whose altered urine levels can
serve as surrogate for non-invasively tracking the progressive
DBD. We also tested the effect of a potential treatment with
intravesical PGE2 administration, which exerts contraction of
underactive bladder utilizing EP receptors. Further study targeting
at EP3 receptor would be worthy of a trial to identify a potential
therapeutic modality for diabetes induced hyposensitive underac-
tive bladder.
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